ALFA Finder| Metric | Q1 FY27 | Q4 FY26 | Q1 FY26 |
|---|---|---|---|
| Revenue from operations | 2788.1 | 2388.5 | 2308.8 |
| Other income | 25.3 | 93.7 | 32.7 |
| Total income | 2813.4 | 2482.2 | 2341.5 |
| Profit before exceptional items & tax | 572.1 | 450.3 | 330.5 |
| Exceptional items | 0.0 | -45.8 | 0.0 |
| Profit before tax | 572.1 | 404.4 | 330.5 |
| Net profit | 424.3 | 306.7 | 232.9 |
| Operating margin | 20.3% | 16.3% | 14.1% |
A dash means the filing did not report that period; n/m means not meaningful (margin on near-zero revenue). Growth is not shown when either period was a loss. Operating profit excludes other income.
| Net profit, year on year | +82.20% |
|---|---|
| Net profit, quarter on quarter | +38.30% |
| Revenue, year on year | +20.80% |
| Operating profit, year on year | +83.60% |
| Operating profit, quarter on quarter | +53.30% |
BSE results filing, NSE: IPCALAB. Figures extracted from the filing.
Ipca Laboratories Ltd: key numbers
- Share price
- ₹1,943.30
- Market cap
- ₹49,302 Cr
- Revenue (annual)
- ₹9,646 Cr
- Net profit (annual)
- ₹1,141 Cr
- P/E (TTM)
- 35.2×Sector 43.8×
- Promoter holding
- 44.72%+0.00% QoQ
- FII holding
- 11.53%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Ipca Laboratories Ltd
All →Ipca Laboratories Earnings Call Transcript: Key Takeaways
Consolidated sales rose about 14% to ₹2,910 Cr and EBITDA margin reached 22.97%, inside the 22-23% guided band. Management reiterated FY27 guidance without a raise.
Ipca Laboratories Q2 FY27 Results: Net Profit ₹389.3 Cr, Up 38.8% YoY
Ipca Laboratories Ltd reported revenue from operations of ₹2,910 Cr (+13.8% YoY) and net profit of ₹389.3 Cr (+38.8% YoY) for Q2 FY27.
- Key figure
- Net profit ₹389.3 Cr · +38.8% YoY
Ipca Laboratories Board Meeting Date
Ipca Laboratories board meeting set for 5 November 2026 to approve Q2 and H1 FY27 unaudited results. Insider trading window remains closed until two days after declaration.
Ipca Laboratories Other Announcement
Ipca Laboratories Ltd submitted its quarterly shareholding pattern for the period ended September 30, 2026, in compliance with Regulation 31(1)(b) of the SEBI Listing Regulations.
Ipca Laboratories Earnings Call Transcript: Key Takeaways
Ipca reported strong Q1FY27 with 21% consolidated revenue growth and EBITDA margins expanding 449bps to 22.88%. Management raised full-year growth and margin guidance based on robust generic and domestic performance.
- Call
- Guides 16% growth
Ipca Laboratories Annual General Meeting
Ipca Laboratories held its 76th Annual General Meeting, covering the adoption of financial statements, dividend declaration, and director appointments. No voting results were included.